AHA 2025 7 - 10 November 2025

Lower Risk of Cardiovascular Events in Patients with Heart Failure Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-HF Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Heart Failure Population)

Authors :

Kim G. Smolderen^1,2; Carlos-Mena Hurtado¹; Victoria Divino³; Zhenxiang Zhao³; Yan Chen⁴; Joanna Boland⁴; Jinlin Song⁴; Briain O Hartaigh³; Prashanth Iyer³; Filip K. Knop⁵; Michael G. Nanna¹

Affiliations

View Details Hide Details

Keywords

Obesity

Cardiovascular Disease

Congress poster

GLP-1 RA

Semaglutide

RWE HEOR

Search Science Hub

Are you a healthcare professional?

Lower Risk of Cardiovascular Events in Patients with Heart Failure Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-HF Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Heart Failure Population)